LivaNova PLC (NASDAQ:LIVN) Stock Holdings Boosted by American Century Companies Inc.

American Century Companies Inc. lifted its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 32.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 150,760 shares of the company's stock after acquiring an additional 37,306 shares during the period. American Century Companies Inc. owned about 0.28% of LivaNova worth $6,982,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its holdings in shares of LivaNova by 22.2% during the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock worth $3,188,000 after purchasing an additional 12,470 shares during the period. Harbor Capital Advisors Inc. bought a new stake in shares of LivaNova during the 4th quarter valued at about $1,954,000. KBC Group NV raised its stake in LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after acquiring an additional 56,580 shares during the period. Rhumbline Advisers lifted its holdings in LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after acquiring an additional 899 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in LivaNova by 29.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after acquiring an additional 1,424 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Needham & Company LLC reiterated a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. The Goldman Sachs Group dropped their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Finally, Stifel Nicolaus reduced their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $61.17.

LivaNova Stock Performance

Shares of NASDAQ LIVN traded down $1.55 during midday trading on Tuesday, reaching $33.85. 1,002,279 shares of the company traded hands, compared to its average volume of 618,664. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 80.60 and a beta of 0.90. The stock has a 50-day moving average price of $42.52 and a 200 day moving average price of $47.76. LivaNova PLC has a 52 week low of $33.41 and a 52 week high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.